CA3256136A1 - CRYSTALLINE SALT FORM OF AN SHP2 INHIBITOR - Google Patents
CRYSTALLINE SALT FORM OF AN SHP2 INHIBITORInfo
- Publication number
- CA3256136A1 CA3256136A1 CA3256136A CA3256136A CA3256136A1 CA 3256136 A1 CA3256136 A1 CA 3256136A1 CA 3256136 A CA3256136 A CA 3256136A CA 3256136 A CA3256136 A CA 3256136A CA 3256136 A1 CA3256136 A1 CA 3256136A1
- Authority
- CA
- Canada
- Prior art keywords
- cancer
- compound
- ppm
- amino
- triazin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/10—Succinic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263323005P | 2022-03-23 | 2022-03-23 | |
| US63/323,005 | 2022-03-23 | ||
| PCT/IB2023/052709 WO2023180898A1 (en) | 2022-03-23 | 2023-03-20 | Crystalline salt form of a shp2 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3256136A1 true CA3256136A1 (en) | 2023-09-28 |
Family
ID=85724850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3256136A Pending CA3256136A1 (en) | 2022-03-23 | 2023-03-20 | CRYSTALLINE SALT FORM OF AN SHP2 INHIBITOR |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250214966A1 (enExample) |
| EP (1) | EP4496629A1 (enExample) |
| JP (1) | JP2025509818A (enExample) |
| KR (1) | KR20240163705A (enExample) |
| CN (1) | CN119095836A (enExample) |
| AR (1) | AR128847A1 (enExample) |
| AU (1) | AU2023238523B2 (enExample) |
| CA (1) | CA3256136A1 (enExample) |
| MX (1) | MX2024011603A (enExample) |
| TW (1) | TW202346282A (enExample) |
| WO (1) | WO2023180898A1 (enExample) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021002880A (es) | 2018-09-14 | 2021-06-04 | Unilever Ip Holdings B V | Evaluacion de la eficacia de composiciones cosmeticas que no se deben enjuagar para proteger la piel de los contaminantes. |
| IL320682A (en) * | 2019-04-02 | 2025-07-01 | Array Biopharma Inc | Protein tyrosine phosphatase inhibitors |
-
2023
- 2023-03-20 KR KR1020247034661A patent/KR20240163705A/ko active Pending
- 2023-03-20 CN CN202380027478.0A patent/CN119095836A/zh active Pending
- 2023-03-20 MX MX2024011603A patent/MX2024011603A/es unknown
- 2023-03-20 EP EP23712623.0A patent/EP4496629A1/en active Pending
- 2023-03-20 WO PCT/IB2023/052709 patent/WO2023180898A1/en not_active Ceased
- 2023-03-20 AU AU2023238523A patent/AU2023238523B2/en active Active
- 2023-03-20 CA CA3256136A patent/CA3256136A1/en active Pending
- 2023-03-20 US US18/848,662 patent/US20250214966A1/en active Pending
- 2023-03-20 JP JP2024555324A patent/JP2025509818A/ja active Pending
- 2023-03-22 AR ARP230100698A patent/AR128847A1/es unknown
- 2023-03-22 TW TW112110698A patent/TW202346282A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025509818A (ja) | 2025-04-11 |
| TW202346282A (zh) | 2023-12-01 |
| WO2023180898A1 (en) | 2023-09-28 |
| US20250214966A1 (en) | 2025-07-03 |
| AR128847A1 (es) | 2024-06-19 |
| CN119095836A (zh) | 2024-12-06 |
| KR20240163705A (ko) | 2024-11-19 |
| AU2023238523B2 (en) | 2025-10-30 |
| AU2023238523A1 (en) | 2024-08-22 |
| MX2024011603A (es) | 2024-09-30 |
| EP4496629A1 (en) | 2025-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12606567B2 (en) | Salts and forms of a WEE1 inhibitor | |
| TWI745831B (zh) | Ｃｄｋ抑制劑之晶形 | |
| US20240190843A1 (en) | Crystalline form of a shp2 inhibitor | |
| CA3026602C (en) | Pyrrolopyrimidine crystal for the preparation of a JAK inhibitor | |
| CN122003424A (zh) | 一种稠环化合物及在kras抑制剂方面的应用 | |
| AU2018259078A1 (en) | C5-anilinoquinazoline compounds and their use in treating cancer | |
| WO2017016463A1 (zh) | Egfr抑制剂及其药学上可接受的盐和多晶型物及其应用 | |
| CN111825658B (zh) | Egfr三突变抑制剂及其应用 | |
| JP7554007B2 (ja) | Ｊａｋ阻害剤化合物及びその使用 | |
| KR102531772B1 (ko) | Cdk4/6 키나아제 억제제를 타겟팅하는 결정형 | |
| AU2023238523B2 (en) | Crystalline salt form of a shp2 inhibitor | |
| US20240246994A1 (en) | Polymorph Of Imidazolidinone Compound, Preparation Method Therefor And Use Thereof | |
| HK40112682A (zh) | Shp2抑制剂的结晶盐形式 | |
| AU2021305347B2 (en) | Salts and forms of a WEE1 inhibitor | |
| RU2684278C1 (ru) | Фумарат пиридиламина и его кристаллы | |
| CN117460725A (zh) | Shp2抑制剂的晶型 | |
| HK40101911A (zh) | Shp2抑制剂的晶型 | |
| CN120344512A (zh) | 氧异吲哚-5-甲酰胺类化合物或其盐、溶剂合物的结晶形式或无定形形式 | |
| CN112209933A (zh) | 含有4-氮杂螺庚烷的btk抑制剂 | |
| HK40058992A (en) | Crystalline form of a cdk inhibitor | |
| CN118891258A (zh) | 含有噻唑环的化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20240919 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20240919 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20240919 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240920 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20250213 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250213 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250213 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250213 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250213 |
|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20250214 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250220 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250224 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250227 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250301 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250301 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250301 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250311 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250320 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20251118 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20251216 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251217 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251217 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251217 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260107 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260107 |